1. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel and T.R. Dawber, High density lipoprotein as a protective factor against coronary heart disease 2 the Frammingham Study, Am. J. Med. 62:707 (1977).
2. N.E. Miller, O. H. Forde, D.S. Thelle and O. D. Mjos, The Tromso Heart Study: high-density lipoprotein and coronary heart disease: a prospective case control study, Lancet 1:965 (1977).
3. M. Heikki Frick et al., Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidiemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease, N. Engl. J. Med. 317:1237 (1987).
4. P. Alaupovic, The physioehemical and immunological heterogeneity of human plasma high density lipoproteins, in: “Clinical and Metabolic Aspects of High Density Lipoproteins”, N.E. Miller and G. J, Miller, eds., Elsevier Science Publishers BV, Amsterdam (1985).
5. P. Alaupovic, W.J. McConathy, M.D. Curry and J.D. Fesmire, Characterization of dyslipoprtoeinemias by apolipoprotein profiles, in: “Lipoproteins and Coronary Atherosclerosis”, G. Nodesa, C. Fragiacamo, R. Fumagolli and R. Paoletti, eds., Elsevier Biomedical Press, Amsterdam (1982).